Literature DB >> 16835260

Nf1+/- mast cells induce neurofibroma like phenotypes through secreted TGF-beta signaling.

Feng-Chun Yang1, Shi Chen, Travis Clegg, Xiaohong Li, Trent Morgan, Selina A Estwick, Jin Yuan, Waleed Khalaf, Sarah Burgin, Jeff Travers, Luis F Parada, David A Ingram, D Wade Clapp.   

Abstract

Neurofibromas are common tumors found in neurofibromatosis type 1 (NF1) patients. These complex tumors are composed of Schwann cells, mast cells, fibroblasts and perineurial cells embedded in collagen that provide a lattice for tumor invasion. Genetic studies demonstrate that in neurofibromas, nullizygous loss of Nf1 in Schwann cells and haploinsufficiency of Nf1 in non-neuronal cells are required for tumorigenesis. Fibroblasts are a major cellular constituent in neurofibromas and are a source of collagen that constitutes approximately 50% of the dry weight of the tumor. Here, we show that two of the prevalent heterozygous cells found in neurofibromas, mast cells and fibroblasts interact directly to contribute to tumor phenotype. Nf1+/- mast cells secrete elevated concentrations of the profibrotic transforming growth factor-beta (TGF-beta). In response to TGF-beta, both murine Nf1+/- fibroblasts and fibroblasts from human neurofibromas proliferate and synthesize excessive collagen, a hallmark of neurofibromas. We also establish that the TGF-beta response occurs via hyperactivation of a novel Ras-c-abl signaling pathway. Genetic or pharmacological inhibition of c-abl reverses fibroblast proliferation and collagen synthesis to wild-type levels. These studies identify a novel molecular target to inhibit neurofibroma formation.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16835260      PMCID: PMC3024714          DOI: 10.1093/hmg/ddl165

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  45 in total

1.  Rhodocetin antagonizes stromal tumor invasion in vitro and other alpha2beta1 integrin-mediated cell functions.

Authors:  Johannes A Eble; Stephan Niland; André Dennes; Alletta Schmidt-Hederich; Peter Bruckner; Georg Brunner
Journal:  Matrix Biol       Date:  2002-11       Impact factor: 11.583

Review 2.  Finding the next Gleevec: FLT3 targeted kinase inhibitor therapy for acute myeloid leukemia.

Authors:  Charles L Sawyers
Journal:  Cancer Cell       Date:  2002-06       Impact factor: 31.743

Review 3.  Two genetic hits (more or less) to cancer.

Authors:  A G Knudson
Journal:  Nat Rev Cancer       Date:  2001-11       Impact factor: 60.716

4.  Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study.

Authors:  Charles L Sawyers; Andreas Hochhaus; Eric Feldman; John M Goldman; Carole B Miller; Oliver G Ottmann; Charles A Schiffer; Moshe Talpaz; Francois Guilhot; Michael W N Deininger; Thomas Fischer; Steve G O'Brien; Richard M Stone; Carlo B Gambacorti-Passerini; Nigel H Russell; Jose J Reiffers; Thomas C Shea; Bernard Chapuis; Steven Coutre; Sante Tura; Enrica Morra; Richard A Larson; Alan Saven; Christian Peschel; Alois Gratwohl; Franco Mandelli; Monique Ben-Am; Insa Gathmann; Renaud Capdeville; Ronald L Paquette; Brian J Druker
Journal:  Blood       Date:  2002-05-15       Impact factor: 22.113

5.  Neurofibromas in NF1: Schwann cell origin and role of tumor environment.

Authors:  Yuan Zhu; Pritam Ghosh; Patrick Charnay; Dennis K Burns; Luis F Parada
Journal:  Science       Date:  2002-05-03       Impact factor: 47.728

6.  Adenoviral vector expressing murine angiostatin inhibits a model of breast cancer metastatic growth in the lungs of mice.

Authors:  S Gyorffy; K Palmer; J Gauldie
Journal:  Am J Pathol       Date:  2001-09       Impact factor: 4.307

7.  Human mast cells stimulate fibroblast proliferation, collagen synthesis and lattice contraction: a direct role for mast cells in skin fibrosis.

Authors:  E Garbuzenko; A Nagler; D Pickholtz; P Gillery; R Reich; F-X Maquart; F Levi-Schaffer
Journal:  Clin Exp Allergy       Date:  2002-02       Impact factor: 5.018

Review 8.  Ras processing as a therapeutic target in hematologic malignancies.

Authors:  Doan Thuy Le; Kevin M Shannon
Journal:  Curr Opin Hematol       Date:  2002-07       Impact factor: 3.284

9.  Inhibition of TGFbeta1 by anti-TGFbeta1 antibody or lisinopril reduces thyroid fibrosis in granulomatous experimental autoimmune thyroiditis.

Authors:  Kemin Chen; Yongzhong Wei; Gordon C Sharp; Helen Braley-Mullen
Journal:  J Immunol       Date:  2002-12-01       Impact factor: 5.422

Review 10.  Inflammation and cancer.

Authors:  Lisa M Coussens; Zena Werb
Journal:  Nature       Date:  2002 Dec 19-26       Impact factor: 49.962

View more
  58 in total

Review 1.  Molecular mechanisms promoting the pathogenesis of Schwann cell neoplasms.

Authors:  Steven L Carroll
Journal:  Acta Neuropathol       Date:  2011-12-11       Impact factor: 17.088

Review 2.  Pathogenesis of plexiform neurofibroma: tumor-stromal/hematopoietic interactions in tumor progression.

Authors:  Karl Staser; Feng-Chun Yang; D Wade Clapp
Journal:  Annu Rev Pathol       Date:  2011-11-07       Impact factor: 23.472

3.  Preclinical Evidence for the Use of Sunitinib Malate in the Treatment of Plexiform Neurofibromas.

Authors:  Michael J Ferguson; Steven D Rhodes; Li Jiang; Xiaohong Li; Jin Yuan; Xianlin Yang; Shaobo Zhang; Saeed T Vakili; Paul Territo; Gary Hutchins; Feng-Chun Yang; David A Ingram; D Wade Clapp; Shi Chen
Journal:  Pediatr Blood Cancer       Date:  2015-09-16       Impact factor: 3.167

4.  Cell of origin and microenvironment contribution for NF1-associated dermal neurofibromas.

Authors:  Lu Q Le; Tracey Shipman; Dennis K Burns; Luis F Parada
Journal:  Cell Stem Cell       Date:  2009-05-08       Impact factor: 24.633

5.  Suppression of proliferation of two independent NF1 malignant peripheral nerve sheath tumor cell lines by the pan-ErbB inhibitor CI-1033.

Authors:  Joshua T Dilworth; Jonathan W Wojtkowiak; Patricia Mathieu; Michael A Tainsky; John J Reiners; Raymond R Mattingly; Chad N Hancock
Journal:  Cancer Biol Ther       Date:  2008-12-07       Impact factor: 4.742

6.  Cross-talk between human mast cells and bronchial epithelial cells in plasminogen activator inhibitor-1 production via transforming growth factor-β1.

Authors:  Seong H Cho; Sun H Lee; Atsushi Kato; Tetsuji Takabayashi; Marianna Kulka; Soon C Shin; Robert P Schleimer
Journal:  Am J Respir Cell Mol Biol       Date:  2015-01       Impact factor: 6.914

7.  Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.

Authors:  Kent A Robertson; Grzegorz Nalepa; Feng-Chun Yang; Daniel C Bowers; Chang Y Ho; Gary D Hutchins; James M Croop; Terry A Vik; Scott C Denne; Luis F Parada; Cynthia M Hingtgen; Laurence E Walsh; Menggang Yu; Kamnesh R Pradhan; Mary K Edwards-Brown; Mervyn D Cohen; James W Fletcher; Jeffrey B Travers; Karl W Staser; Melissa W Lee; Marcie R Sherman; Cynthia J Davis; Lucy C Miller; David A Ingram; D Wade Clapp
Journal:  Lancet Oncol       Date:  2012-10-23       Impact factor: 41.316

8.  Prognostic value of tumor-infiltrating mast cells in outcome of patients with esophagus squamous cell carcinoma.

Authors:  Ashraf Fakhrjou; Seid Mahdi Niroumand-Oscoei; Mohamad Hosein Somi; Morteza Ghojazadeh; Shahnaz Naghashi; Shabnam Samankan
Journal:  J Gastrointest Cancer       Date:  2014-03

9.  Expression analysis of genes lying in the NF1 microdeletion interval points to four candidate modifiers for neurofibroma formation.

Authors:  B Bartelt-Kirbach; M Wuepping; M Dodrimont-Lattke; D Kaufmann
Journal:  Neurogenetics       Date:  2008-10-11       Impact factor: 2.660

10.  Nf1-dependent tumors require a microenvironment containing Nf1+/-- and c-kit-dependent bone marrow.

Authors:  Feng-Chun Yang; David A Ingram; Shi Chen; Yuan Zhu; Jin Yuan; Xiaohong Li; Xianlin Yang; Scott Knowles; Whitney Horn; Yan Li; Shaobo Zhang; Yanzhu Yang; Saeed T Vakili; Menggang Yu; Dennis Burns; Kent Robertson; Gary Hutchins; Luis F Parada; D Wade Clapp
Journal:  Cell       Date:  2008-10-31       Impact factor: 41.582

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.